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Abstract
Background: Klotho is a discovered aging suppressor gene, and its overexpression in mice extends the life span of
the animal. Recently, Klotho is also identified as a tumor suppressor gene in variety of tumors; however, the
potential role and the antitumor mechanism remain unclarified in liver cancers.
Methods: RT-PCR and western blotting analysis were used to detect the expression of Klotho, β-catenin, C-myc,
and Cyclin D1. MTT assay was used to detect the survival rates of HepG2 and SMMC-7721 cells. Colony formation
assay was used to test the proliferation ability in Klotho transfected cells. FACS was used to detect the cell
apoptosis rate in different groups.
Results: The results showed that lower expression of Klotho were found in liver cancer cell lines than the
immortalized liver cell L02. Also, MTT assay results found that overexpression or recombinant Klotho administration
suppressed the proliferation of liver cancer cells HepG2 and SMMC-7721. Moreover, the colony formation assay
results showed that the number of colonies was significantly lower in the cells with transfection with pCMV-Klotho
than the controls. Thus, functional analysis demonstrated that Klotho expression inhibited the proliferation of liver
cancer cells and Klotho worked as an important antitumor gene in tumor progression. Next, the mechanism was
partly clarified that Klotho expression induced cell apoptosis in HepG2 and SMMC-7721 cells, and this phenomenon
was mainly involved in the Wnt/β-catenin signaling pathway. The western blotting analysis revealed that
overexpression or recombinant administration of Klotho obviously decreased the expression levels of β-catenin,
C-myc, and Cyclin D1 in HepG2 cells. Most importantly, the antitumor mechanism for Klotho due to that
overexpression of Klotho not only decreased the endogenous β-catenin levels but also inhibited the nuclear
translocation of β-catenin to delay the cell cycle progression.
Conclusions: Klotho was a tumor suppressor gene, and overexpression of Klotho suppressed the proliferation of
liver cancer cells partly due to negative regulation of Wnt/β-catenin signaling pathway. So, Klotho might be used as
a potential target, and the study will contribute to treatment for therapy of liver cancer patients.
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Background
Liver cancer is one of the most lethal cancers in the
world, and its mortality ranks the third in cancer deaths
[1, 2]. Each year, about 60 million people worldwide die
of liver cancer, and this has a growing trend. Primary
liver cancers mainly include two types: hepatocellular
carcinoma (HCC) and intrahepatic bile duct cancer [3].
In the developing countries, hepatitis B and hepatitis C
are the risk factors responsible for most cases of primary
liver cancer [4, 5]. Although the risk factors are prevent-
able, the incidence of liver cancer is actually rising in
many developing countries. The most common risk fac-
tor in the USA is alcohol abuse, followed by obesity and
diabetes [6, 7]. The incidence has gotten over 30,000
cases each year in the USA. Thus, it is very important to
elucidate the mechanism for the occurrence and devel-
opment of hepatocellular carcinoma.
Klotho was a new identified aging suppressor gene,
which is highly conserved between human and mouse,
with 86 % amino acid identity [8]. The gene encoded a
membrane protein and defect in Klotho gene expression
in the mouse that causes a syndrome of aging, including
a short lifespan [9]. Recently, the relationship of Klotho
expression and cancer progression has been studied
[10–12]; however, the role and mechanism in a variety
of cancers remain unclear. Lu et al. had a clinical follow-
up study of 189 epithelial ovarian cancer patients, which
demonstrated that high expression of secreted Klotho
was associated with increased risk of disease progression
and death and positively correlated with the expression
of IGF-I and IGFBP-3 but not with IGF-II [11]. However,
Wang et al. reported that Klotho, as a novel tumor sup-
pressor gene, was epigenetically inactivated and silenced
through promoter hypermethylation in gastric cancer,
and the promoter methylation of Klotho could be used
to predict the prognosis of gastric cancer patients [13].
In human colon cancers, expression of Klotho was
downregulated and correlated with tumor invasion and
Dukes staging, while overexpression of Klotho inhibited
cell proliferation and invasion through inhibition of
IGF1R-mediated PI3K/AKT pathway in colon cancer
cells [14]. Moreover, Klotho inhibited the capacity of cell
migration and invasion in cervical cancer, in vitro restor-
ation of Klotho expression in SiHa cells resulting in a
decreased cell motility and invasiveness through upregu-
lation of E-cadherin, downregulation of N-cadherin, and
reduced expression of MMP-7 and MMP-9 [15].
However, the relationship and association between the
expression of Klotho and primary liver cancers is not
clarified till now [16]. In the present study, we explored
the effects and possible mechanisms relating to Klotho
in human liver cancer cell lines, and the clarification of
the association and mechanism would contribute to
treatment for therapy of liver cancer patients.
Methods
Agent and cell lines
Recombinant human Klotho (rKlotho) is a 65–70 kDa
glycoprotein containing 516 amino acid residues. The
protein of rKlotho was obtained from Sigma Corporation
(cat. SRP3102). The myc-tagged Klotho expression vector
(pCMV6-Klotho) and the control vector (pCMV6) were
designed and obtained from OriGene corporation
(Rockville, MD, USA). The liver cancer cell lines
HepG2, SMMC-7721, and BEL-7404 were obtained
from American Type Culture Collection (ATCC,
Rochville, MD. USA). The normal liver cancer cells
L02 was purchased from Junrui Coporation (Shanghai,
China). The liver cancer cells were cultured in DMEM
medium (GIBCO, Gaithersburg, MD, USA) supplemented
with 10 % fetal bovine serum and cultured at 37 °C with
5 % CO2 in a humidified atmosphere.
MTT assay
Cell proliferation is tested by MTT assay. Generally, the
human liver cancer cells HepG2 and SMMC-7721 cells
were planted into 48-well plates. Then, the cells were
cultured for 8 h and transfected with p CMV6-Klotho
and p CMV-6 vector for 24, 48, 72, and 96 h. Finally,
MTT agent was added into the medium, and the purple
crystals were dissolved with DMSO. The liquid was
transferred into 96-well plates and read on a microplate
reader at a test wavelength of 490 nm and a reference
wavelength of 570 nm.
RT-PCR assay
The RNApure kit (Bioteke, Beijing, China) was used to
extract total RNA, and reverse transcriptase (RT) Super-
Script III (Invitrogen BV, Carlsbad, CA) was used to
transcript the cDNA. The primer sequences were as fol-
lows: for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), 5′-GAAGGTGAAGGTCGGAGTC-3′ (sense)
and 5′-GAAGATGGTGATGGGATTTC-3′ (antisense)
and for Klotho, 5′-ACCTGGTGGCGCACAACC-3′(sense)
and 5′-TTGGCAAACCAACCTAGTACA-3′. The Klotho
PCR reaction condition is that 94 °C 5 min, followed by
30 cycles of 94 °C for 30 s, 55 °C for 30 s, and 72 °C for
30 s, and finally, elongation is 72 °C for 10 min. The
GAPDH reaction condition is similar to Klotho but for the
annealing temperature it is 55 °C for 30 s.
Colony formation assay
The liver cancer cells were transfected with pCMV6-
Klotho and pCMV-6 vector for stable cell lines. For col-
ony formation assay, the cells were plated into 6-well
plate. After 8 h, the cells transfected with Klotho or con-
trol vector were cultured for 14 days, and the medium
was refreshed every 3 days. Then, methanol was used to
fix the colonies (≥50 cells per colony). They were stained
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with 1.25 % crystal violet and counted under a light
microscope.
Flow cytometric analysis
Annexin V-FITC/PI dual staining analysis is used for de-
tection of the apoptosis rates in human lung cancer cells
according to the kit protocols (Santacruz, USA). Briefly,
the liver cancer cells (4 × 105 cells/well) were plated into
6-well plate and transfected with pCMV6-Klotho and
pCMV6 vector for 48 h. Then, the cells were washed
with ice PBS buffer for three times and resuspended in
binding buffer with HEPES–NaOH 10 mM pH 7.4,
25 mM CaCl2, and 144 mM NaCl. At last, the staining
dye of Annexin V (0.1 μg/μl) and PI (0.05 μg/μl) were
added for incubation in the dark for 30 min on ice, and
the cells were subjected to FACS analysis.
Western blot analysis
The liver cancer cells were plated into 48-well plates and
cultured for 8 h for adherence. Then, the cells were
transfected with pCMV6-Klotho and p CMV-6 vector
for 48 h. The pCMV6 vector was used as the control.
The other treatment was that the cells were treated with
rKlotho or BSA at the concentration of 250 ng/mL. BSA
was used as the negative control. Next, the cells were
washed with ice-cold PBS buffer, and cell lysates were
prepared for PAGE. The primary antibodies used were
included; the anti-beclin 1, anti-LCI, anti-LC-II, anti-C-
myc, anti-Cyclin D1, and anti-GAPDH were all pur-
chased from Santa Cruz biotechnology. The primary
antibodies of β-tublin (ab6046), lamin B1(ab16048), and
Anti-Klotho (ab18131) were obtained from Abcam cor-
poration. The horseradish peroxidase-conjugated goat
anti-mouse secondary antibody was purchased from
Abgent Corporation.
Statistical analysis
All of the data was analyzed using SPSS software. All of
the experiments were repeated three times in duplicates.
Student’s t test was used to assess the significance of
the data, and all of the data are showed as mean ± SD.
P < 0.01 means that there is significant difference.
Results
Low level of Klotho is detected in liver cancer cell lines
To explore the Klotho expression of Klotho in liver can-
cer cell lines, we analyzed Klotho levels in a panel of four
liver cancer cell lines by RT-PCR and western blotting
analysis. Low mRNA levels and protein levels were de-
tected in liver cancer cell lines, such as Bel-7404, HepG2,
SMMC-7721 etc., compared with the immortalized liver
cell L02 (Fig. 1).
Overexpression or recombinant Klotho administration
suppresses the proliferation of liver cancer cells
We next evaluated the effect of Klotho on cell prolifera-
tion of liver cancer cells. HepG2 and SMMC-7721 cells
were transfected with expression vector of pCMV6-
Klotho for 24, 48, 72, and 96 h. As shown in Fig. 2a, the
OD490 values were obviously decreased in the group
transfected with p CMV6-Klotho than those of p CMV6
vector, suggesting that the cell proliferation was signifi-
cantly suppressed as higher expression of Klotho. Add-
itionally, as shown in Fig. 2b, the HepG2 cells and
SMMC-7721 cells were treated with recombinant Klotho
at the concentration of 300 ng/mL for 24, 48, 72, and
96 h. The results demonstrated that rKlotho administra-
tion inhibited cell growth of liver cancer cells HepG2
and SMMC-7721, and higher expression of Klotho was
accompanied with lower proliferation of liver cancer
cells. All of the data collectively revealed that Klotho ex-
pression inhibited the proliferation of liver cancer cells.
Klotho expression suppresses liver cancer cell growth by
colony formation assay
In order to clarify the functional relevance of Klotho in
liver cancer progression, colony formation assay is per-
formed in liver cancer cells after Klotho expression. The
Fig. 1 Low level of Klotho is detected in the liver cancer cell lines.
The liver cancer cells (5 × 105 cells/well) were plated into 6-well
plate. After 8 h, the endogenous Klotho levels in a panel of four liver
cancer cell lines were detected with RT-PCR (a) and western blotting
analysis (b). L02 is an immortalized liver cell line, and GAPDH is used
as an internal reference
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liver cancer cell line HepG2 and SMMC-7721 were
transfected with p CMV6-Klotho and control plasmid
(pCMV6 vector), and the cells were cultured for 10 days.
As shown in Fig. 3, the number of colonies was signifi-
cantly lower in the cells with transfection with pCMV-
Klotho than the controls. Taken together, Klotho expres-
sion inhibits the proliferation of liver cancer cells, and
Klotho plays an important antitumor role as a potential
tumor suppressor.
Klotho expression induces cell apoptosis in human liver
cancer cells
It is proved that overexpression or recombinant Klotho
administration could inhibit the proliferation of liver
cancer cells. In order to identify whether cell apoptosis
is induced in cancer cells with overexpression of Klotho,
FACS analysis was used by dural staining with PI and
Annexin V-FITC. As shown in Fig. 4, the apoptosis rates
in HepG2 cells transfected by p CMV6-Klotho was signifi-
cantly higher than the control cells (P < 0.01), and this was
consistent with the situation in SMMC-7721 cells.
Klotho levels negatively correlate with Wnt/β-catenin
signaling pathway in HepG2 cells
It is reported that Wnt/β-catenin signaling pathway is ab-
normally expressed in liver cancer cells. In order to explore
the relationship between the tumor suppressor, Klotho and
Wnt/β-catenin signaling pathway, the HepG2 cells were
transfected with p CMV6-Klotho and control plasmid p
CMV6. The expression levels of Klotho, β-catenin, C-myc,
and Cyclin D1 were detected by western blot. As shown in
Fig. 5a, the HepG2 cells in p CMV6-Klotho transfected
group had higher levels of Klotho, accompanied by lower
expression of β-catenin, C-myc, and Cyclin D1. Consistent
with this finding, the HepG2 cells were treated with
recombinated Klotho for 48 h, and the results showed in-
creased Klotho expression concomitant with decreased
levels of β-catenin, C-myc, and Cyclin D1 (Fig. 5b).
Overexpression of Klotho decreases endogenous
β-catenin level and inhibits its nuclear translocation
The activation of Wnt/β-catenin signaling pathway is
that β-catenin was translocated into the nucleus.
Fig. 2 Overexpression or recombinant Klotho administration suppresses the proliferation of liver cancer cells. a The liver cancer cells (2 × 104
cells/per well) were plated into 48-well plate. After 8 h, the cells were transfected with p CMV6-Klotho and control vector for 24, 48, 72, and 96 h.
The cells transfected by p CMV6 vector were used as the controls. Data are shown as means ± SD. **p < 0.01 compared with control cells. b The
liver cancer cells HepG2 and SMMC-7721 (1 × 103 cells/per well) were plated into 96-well plate. After 8 h, the cells were treated with recombi-
nated Klotho protein and control protein BSA for 24, 48, 72, and 96 h. Data are shown as means ± SD. **p < 0.01 compared with the cells treated
with BSA
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Next, we wanted to know whether overexpression of
Klotho would affect the translocation of β-catenin.
Thus, we detected the distribution of β-catenin in
cytoplasm and the nucleus. As shown in Fig. 6, in
pCMV-Klotho-transfected HepG2 cells, the expres-
sion levels of β-catenin obviously increased in cyto-
plasm compared with those in control cells. The β-
catenin levels in cytoplasm and nucleus were both
decreased in p CMV6-Klotho transfected cells, ac-
companied by lower expression levels of C-myc and
Cyclin D1. All of the data revealed that overexpres-
sion of Klotho decreased the endogenous expression
of β-catenin and inhibited the translocation of β-
catenin from cytoplasm into nucleus. Additionally,
the transcription of target genes in the downstream
of wnt/β-catenin was also downregulated, such as C-
myc and Cyclin D1, which was involved in cell cycle
progression.
Discussion
Primary hepatocellular carcinoma is a common malig-
nancy in the world [17]. With the emergence of the
problem, such as an aging population and environmental
pollution, the incidence of liver cancer arises rapidly and
liver cancer has become the second killer in China [18,
19]. It not only gives the pain and psychological burden
for patients but also gives serious economic burden to
the family and the community [20, 21]. Thus, it has be-
come the focus of medical research and hotspots in
China to investigate the molecular mechanisms of the
development and progression of liver cancer, which
could give some new clues for the prognosis and treat-
ment on hepatocellular carcinoma.
Klotho has been newly identified as an antiaging gene
that is involved in the suppression of several aging phe-
notypes [22–25]. But the potential role and the antitu-
mor mechanism remains unclear in human liver cancers.
Fig. 3 Klotho expression suppresses liver cancer cell growth by colony formation assay. a The liver cancer cell line of HepG2 and SMMC-7721 was
used for colony formation assay. b Histogram of clone formation ratio was shown in pCMV6-Klotho group, control plasmid group, or untreated
group. **p < 0.01, compared with the cells transfected with pCMV6-vector
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In the present study, we first explored the expression
levels in a panel of three liver cancer cell lines, HepG2,
SMMC-7721, and Bel-7404, and the normal liver cell
L02. As expected, the expression levels of Klotho in three
liver cancer cell lines were obviously decreased than
those in L02 cells. The MTT assay proved that overex-
pression or recombinant Klotho administration in liver
cancer cells significantly suppressed the proliferation of
cancer cells. This was consistent with the results from
the colony formation assay. Moreover, FACS analysis re-
sults demonstrated that overexpression of Klotho in-
duced cell apoptosis in HepG2 and SMMC-7721 cells.
All of the data revealed that Klotho worked as an im-
portant antitumor gene in liver cancer progression al-
though some other paper found that high levels of
Klotho promoted cancer progression. One of the probable
reasons is that Klotho may have different role in the
progression and development of various tumors.
Then, we further explore the mechanism of Klotho in-
volving in the progression of liver cancers. It has re-
ported that overexpression of Klotho inhibits growth and
invasion through inhibition of IGF1R-mediated PI3K/
AKT pathway in colon cancer cells [14]. In lung cancer
cells, Klotho, as a novel secreted Wnt antagonist, could
inhibit activation of Wnt /beta-catenin signaling pathway,
in a dose-dependent manner [23]. As we know, Wnt/
β-catenin signaling pathway is essential for development
and tumorigenesis, and this signaling pathway is abnor-
mally activated in the progress of hepatocellular carcin-
oma. Beta-catenin is an important component in Wnt/
β-catenin pathway by being a coactivator of LEF/TCF
transcription factors. In pathological conditions, cytoplasmic
β-catenin leads to its nuclear accumulation and form the
complex with LEF/TCF transcription factors. Then, the
LEF/TCF target genes are transactivated, such as C-myc
and Cyclin D1, which promote cell cycle progression.
Fig. 4 Klotho expression induces cell apoptosis in human liver cancer cells. a The HepG2 cells were plated into 6-well plate and were transfected
with pCMV6-Klotho and pCMV6 vector for 48 h. Then, the cells were fixed, dispersed, and stained with Annexin V and PI. The cell apoptosis rate
was detected by flow cytometry analysis. The histogram of HepG2 (b) and SMMC-7721 (c) were shown. The cells transfected with pCMV6 vector
were used as negative controls. **p < 0.01, compared with negative control
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Fig. 5 Klotho levels negatively correlate with Wnt/β-catenin signaling pathway in HepG2 cells. a The HepG2 cells with the density of 3 × 104 cells/per
well were plated in 24-well plates. Eight hours later, pCMV6-Klotho and p CMV6 vector were transfected into HepG2 cells. After 48 h, the expression of
Klotho, β-catenin, C-myc, and Cyclin D1 was detected by western blotting. b The HepG2 cells with the density of 1 × 103 cells/per well were plated in
24-well plates. Eight hours later, recombinated Klotho and BSA were added into HepG2 cells, respectively. After 48 h, the expression of Klotho,
β-catenin, C-myc, and Cyclin D1 was detected by western blotting
Fig. 6 Overexpression of Klotho decreases endogenous β-catenin level and inhibits its nuclear translocation. The liver cancer cells (2 × 103 cells/per
well) were plated into 6-well plate, and the cells were transfected with pCMV6-Klotho and the control plasmid after 8 h. Cell lysates were prepared for
detecting of β-catenin in cytoplasm and nucleus by western blot analysis after transfection for 48 h. And, the expression levels of cyclin D1 and C-myc
were also detected by western blotting analysis. β-tublin was used as an internal reference in cytoplasm, and lamin B1 was used as the internal
reference in nucleus
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Here, we also detected the association of Klotho
expression with Wnt/β-catenin signaling pathway.
The western blotting analysis showed that high levels
of Klotho were associated with decreased levels of
β-catenin. Importantly, the nuclear translocation of
β-catenin was also suppressed in HepG2 cells. Additionally,
the target genes of the downstream (C-myc and Cyclin D1)
were downregulated. All of the data demonstrated that
overexpression of Klotho suppressed the proliferation of
liver cancer cells and promoted cell apoptosis partly due
to negative regulation of Wnt/β-catenin signaling
pathway. Thus, Klotho might be used as a potential
target, and the study will contribute to treatment for
therapy of liver cancer patients.
Conclusions
Klotho was a tumor suppressor gene and overexpression
of Klotho suppressed the proliferation of liver cancer
cells partly due to negative regulation of Wnt/β-catenin
signalling pathway. So, Klotho might be used as a potential
target and the study will contribute to treatment for
therapy of liver cancer patients.
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